Chemoprevention of breast cancer in postmenopausal women

Breast Disease

Volumn 24, Issue 1, 2005, Pages 79-92

  Geller, Brian A ^a   Vogel, Victor G ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Aromatase inhibitors; Breast cancer; Chemoprevention; Raloxifene; Tamoxifen

Indexed keywords

ACETYLSALICYLIC ACID; ANASTROZOLE; ANTIESTROGEN; AROMATASE; AROMATASE INHIBITOR; ESTROGEN; EXEMESTANE; LETROZOLE; PLACEBO; RALOXIFENE; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN ISCHEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CATARACT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DEPRESSION; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG RECEPTOR BINDING; ENDOMETRIUM CANCER; ENZYME INHIBITION; ESTROGEN BLOOD LEVEL; FAMILY HISTORY; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; FRAGILITY FRACTURE; HEALTH SERVICE; HOT FLUSH; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MEDICAL SOCIETY; MENSTRUAL IRREGULARITY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEXUAL DYSFUNCTION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UNITED STATES; UTERUS CANCER; VAGINA BLEEDING; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM;

EID: 33747356530     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/bd-2006-24107     Document Type: Article

References (41)

1. A. Jemal et al., Cancer statistics, 2005, CA Cancer J Clin 55 (2005), 10-30.
2. B.A. Box and C.A. Russell, Breast Cancer, in: Manual of Clinical Oncology, (5th ed.), D.A. Casciato, ed., Lippincott Williams and Wilkins, 2004, Philadelphia, PA, 2004, p. 235.
3. V.G. Vogel, Chemoprevention: Reducing breast cancer risk, in: Management of patients at high risk for breast cancer, V.G. Vogel, ed., Blackwell Science Inc., Malden, MA, 2001, pp. 201-227.
4. M.H. Gail et al., Projecting individualized probabilities of developing breast cancer for white females who are being examined annually, J Natl Cancer Inst 81 (1989), 1879-1886.
5. J.A. Cauley et al., Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation, Breast Cancer Res Treat 65 (2001), 125-134.
6. J. Cuzick et al., First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial, Lancet 360 (2002), 817-824.
7. B. Fisher et al., Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, J Natl Cancer Inst 90 (1998), 1371-1388.
8. S. Martino et al., Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene, J Natl Cancer Inst 96 (2004), 1751-1761.
9. T. Powles et al., Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial, Lancet 352 (1998), 98-101.
10. T.J. Powles et al., The Royal Marsden Hospital pilot tamoxifen chemoprevention trial, Breast Cancer Res Treat 31 (1994), 73-82.
11. U. Veronesi et al., Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study, Lancet 352 (1998), 93-97.
12. D.B. Muchmore, Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects, Oncologist 5 (2000), 388-392.
13. C.K. Osborne, Tamoxifen in the treatment of breast cancer, N Engl J Med 339 (1998), 1609-1618.
14. I. Kloos et al., Tamoxifen-related uterine carcinosarcomas occur under/ after prolonged treatment: Report of five cases and review of the literature, Int J Gynecol Cancer 12 (2002), 496-500.
15. A. Manni et al., Antihormone treatment of stage IV breast cancer, Cancer 43 (1979), 444-450.
16. L.R. Morgan, Jr., et al., Therapeutic use of tamoxifen in advanced breast cancer: Correlation with biochemical parameters, Cancer Treat Rep 60 (1976), 1437-1443.
17. H. Westerberg et al., Anti-oestrogen therapy of advanced mammary carcinoma, Acta Radiol Ther Phys Biol 15 (1976), 513-518.
18. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials, Lancet 352 (1998), 930-942.
19. R. Day et al., Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study, J Clin Oncol 17 (1999), 2659-2669.
20. J.A. Kellen, Raloxifene, Curr Drug Targets 2 (2001), 423-425.
21. A. Cranney and J.D. Adachi, Benefit-risk assessment of raloxifene in postmenopausal osteoporosis, Drug Safety 28 (2005), 721-730.
22. E.R. Simpson et al., Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis, Endocr Rev 15 (1994), 342-355.
23. W.R. Miller, Biological rationale for endocrine therapy in breast cancer, Best Pract Res Clin Endocrinol Metab 18 (2004), 1-32.
24. M. Baum et al., Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses, Cancer 98 (2003), 1802-1810.
25. A. Howell et al., Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer, Lancet 365 (2005), 60-62.
26. E.P. Winer et al., American Society of Clinical Oncology Technology Assessment on the Use of Aromatase inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004, J Clin Oncol 23 (2005), 619-629.
27. P.E. Goss et al., A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer, N Engl J Med 349 (2003), 1793-1802.
28. R. Day et al., Tamoxifen and depression: More evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study, J Natl Cancer Inst 93 (2001), 1615-1623.
29. B. Fisher et al., Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, J Natl Cancer Inst 97 (2005), 1652-1662.
30. J.P. Costantino and V.G. Vogel, Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials: An alternative view, Clin Breast Cancer 2 (2001), 41-46.
31. U. Veronesi et al., Italian randomized trial among women with hysterectomy: Tamoxifen and hormone-dependent breast cancer in high-risk women, J Natl Cancer Inst 95 (2003), 160-165.
32. J. Cuzick et al., Overview of the main outcomes in breast-cancer prevention trials, Lancet 361 (2003), 296-300.
33. R.T. Chlebowski et al., American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition, J Clin Oncol 20 (2002), 3328-3343.
34. L.S. Kinsinger et al., Chemoprevention of breast cancer: A summary of the evidence for the US Preventive Services Task Force, Ann Intern Med 137 (2002), 59-69.
35. A.N. Freedman et al., Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention, J Natl Cancer Inst 95 (2003), 526-532.
36. M.H. Gail et al., Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer, J Natl Cancer Inst 91 (1999), 1829-1846.
37. P.D. Delmas et al., Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial, J Clin Endocrinol Metab 87 (2002), 3609-3617.
38. http://www3.cancer.gov/prevention/accomplishments.html.
39. V.G. Vogel et al., National surgical adjuvant breast and bowel project update: Prevention trials and endocrine therapy of ductal carcinoma in situ, Clin Cancer Res 9 (2003), 495S-501S.
40. P.E. Goss and K. Strasser, Aromatase inhibitors in the treatment and prevention of breast cancer, J Clin Oncol 19 (2001), 881-894.
41. G. Bevilacqua et al., Exemestane for the prevention of breast cancer in postmenopausal unaffected carriers of BRCA1/2 mutations: Aromasin Prevention Study (ApreS), Breast Cancer Res Treatment 69 (2001), 226 (Abstract #139).